RU2617392C2 - Применение arry-520 для лечения рака у пациентов с низким уровнем акг - Google Patents

Применение arry-520 для лечения рака у пациентов с низким уровнем акг Download PDF

Info

Publication number
RU2617392C2
RU2617392C2 RU2015108740A RU2015108740A RU2617392C2 RU 2617392 C2 RU2617392 C2 RU 2617392C2 RU 2015108740 A RU2015108740 A RU 2015108740A RU 2015108740 A RU2015108740 A RU 2015108740A RU 2617392 C2 RU2617392 C2 RU 2617392C2
Authority
RU
Russia
Prior art keywords
arry
acg
cancer
patient
administered
Prior art date
Application number
RU2015108740A
Other languages
English (en)
Russian (ru)
Other versions
RU2015108740A (ru
Inventor
Карин БРАУН
Рональд Б. ФРАНКЛИН
Гэри П. ХИНГОРАНИ
Кевин С. ЛИТВИЛЕР
Брайан Дж. ТАНКВИСТ
Дункан Х. ВОКЕР
Original Assignee
Эррэй Биофарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50101460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2617392(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эррэй Биофарма Инк. filed Critical Эррэй Биофарма Инк.
Publication of RU2015108740A publication Critical patent/RU2015108740A/ru
Application granted granted Critical
Publication of RU2617392C2 publication Critical patent/RU2617392C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2015108740A 2012-08-13 2013-08-13 Применение arry-520 для лечения рака у пациентов с низким уровнем акг RU2617392C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261682682P 2012-08-13 2012-08-13
US61/682,682 2012-08-13
US201261734149P 2012-12-06 2012-12-06
US61/734,149 2012-12-06
US201361829779P 2013-05-31 2013-05-31
US61/829,779 2013-05-31
PCT/US2013/054807 WO2014028543A1 (en) 2012-08-13 2013-08-13 Arry-520 for use in treating cancer in a patient with low aag

Publications (2)

Publication Number Publication Date
RU2015108740A RU2015108740A (ru) 2016-09-27
RU2617392C2 true RU2617392C2 (ru) 2017-04-24

Family

ID=50101460

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015108740A RU2617392C2 (ru) 2012-08-13 2013-08-13 Применение arry-520 для лечения рака у пациентов с низким уровнем акг

Country Status (19)

Country Link
US (1) US20150231117A1 (https=)
EP (1) EP2882436A1 (https=)
JP (1) JP2015524845A (https=)
KR (1) KR20150042280A (https=)
CN (1) CN104869995A (https=)
AU (1) AU2013302762A1 (https=)
BR (1) BR112015003192A2 (https=)
CA (1) CA2881937A1 (https=)
CL (1) CL2015000348A1 (https=)
CR (1) CR20150134A (https=)
HK (1) HK1206275A1 (https=)
IL (1) IL237227A0 (https=)
IN (1) IN2015KN00676A (https=)
MX (1) MX2015002018A (https=)
NZ (1) NZ631362A (https=)
PH (1) PH12015500306A1 (https=)
RU (1) RU2617392C2 (https=)
SG (1) SG11201501106TA (https=)
WO (1) WO2014028543A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2385867C2 (ru) * 2004-05-21 2010-04-10 Новартис Аг Замещенные производные хинолина как ингибиторы митотического кинезина
WO2010045624A1 (en) * 2008-10-16 2010-04-22 Array Biopharma Inc. Inhibitors of mitosis for increasing apoptosis in therapy
RU2413720C2 (ru) * 2004-05-06 2011-03-10 Цитокинетикс, Инк. Химические составы, композиции и способы их использования

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
US9561214B2 (en) 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2413720C2 (ru) * 2004-05-06 2011-03-10 Цитокинетикс, Инк. Химические составы, композиции и способы их использования
RU2385867C2 (ru) * 2004-05-21 2010-04-10 Новартис Аг Замещенные производные хинолина как ингибиторы митотического кинезина
WO2010045624A1 (en) * 2008-10-16 2010-04-22 Array Biopharma Inc. Inhibitors of mitosis for increasing apoptosis in therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GONCALVES P. et al. A phase 1 safety and pharmacokinetic study of ARRY-520 in solid tumors//7 june 2010, XP055086253 найдено в Интернет на (http://arraybiopharma.com/files/6213/9810/7990/PubAttachment387.pdf). *
P GONCALVES, SAUSVILLE E, EDELMAN M, PANDYA N, HOULEHAN M, FREEMAN B, SIMMONS H, STALLINGS J, PTASZYNSKI M, LORUSSO P: "A Phase 1 Safety and Pharmacokinetic Study of ARRY-520 in Solid Tumors", 7 June 2010 (2010-06-07), XP055086253, Retrieved from the Internet <URL:http://www.arraybiopharma.com/_documents/Publication/PubAttachment387.pdf> [retrieved on 20131031] *

Also Published As

Publication number Publication date
BR112015003192A2 (pt) 2017-08-08
MX2015002018A (es) 2015-10-09
US20150231117A1 (en) 2015-08-20
JP2015524845A (ja) 2015-08-27
CA2881937A1 (en) 2014-02-20
KR20150042280A (ko) 2015-04-20
PH12015500306A1 (en) 2015-04-20
HK1206275A1 (en) 2016-01-08
CN104869995A (zh) 2015-08-26
NZ631362A (en) 2016-09-30
AU2013302762A1 (en) 2014-10-02
CL2015000348A1 (es) 2015-04-24
EP2882436A1 (en) 2015-06-17
CR20150134A (es) 2015-05-06
IN2015KN00676A (https=) 2015-07-17
IL237227A0 (en) 2015-04-30
RU2015108740A (ru) 2016-09-27
WO2014028543A1 (en) 2014-02-20
SG11201501106TA (en) 2015-06-29

Similar Documents

Publication Publication Date Title
US20230125427A1 (en) Methods of measuring signaling pathway activity for selection of therapeutic agents
JP5795311B2 (ja) 抗体ベースのアレイを使用する胃癌療法のための薬物選択
Huang et al. Clinical functional proteomics of intercellular signalling in pancreatic cancer
US20140024548A1 (en) Drug selection for malignant cancer therapy using antibody-based arrays
KR20120110168A (ko) 종양원성 융합 단백질을 검출하기 위한 근접-매개 검정법
MX2012008153A (es) Metodos para predecir la respuesta a terapia de cancer de mama triple negativo.
KR20100063011A (ko) 항체­기반 어레이를 사용한 폐 암 치료를 위한 약물 선별법
KR20140020318A (ko) 위암 환자의 생존률 예측 및 개선 방법
Peng et al. Identification of Bruceine A as a novel HSP90AB1 inhibitor for suppressing hepatocellular carcinoma growth
Coggins et al. Pharmacokinetics of GS‐441524 following intravenous remdesivir in six cats and results of therapeutic drug monitoring during treatment of feline infectious peritonitis: 22 cases (2021–2024)
RU2617392C2 (ru) Применение arry-520 для лечения рака у пациентов с низким уровнем акг
Breidert et al. Functional molecular network analysis enables prediction of response to vedolizumab therapy in anti-TNF refractory IBD patients
US20200191772A1 (en) Combined anticancer agent sensitivity determination marker
US20160025730A1 (en) Methods of selecting combination therapy for colorectal cancer patients
CN118345171B (zh) Mef2a作为预测结直肠癌患者对奥沙利铂治疗敏感性的标志物的应用
EP3039429B1 (en) Polyp recurrence
CN121969391A (zh) 上调p53蛋白表达或激活p53功能的药物与DNA烷化剂联用治疗癌症
Soudarpally et al. Protein Biomarker in Focal Cortical Dysplasia: Molecular Clues to Pathogenesis
Ndovi Compartmental kinetics of antiretroviral drugs (ARVs) in the human male genital tract